A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Amphotericin B has long been the standard treatment for candidemia, but its use is complicated by its toxicity. More recently, fluconazole, a water-soluble triazole with activity against candida species and little toxicity, has become available. We conducted a multicenter randomized trial that compared amphotericin B with fluconazole as treatment for candidemia. METHODS: To be eligible, patients had to have a positive blood culture for candida species, a neutrophil count > or = 500 per cubic millimeter, and no major immunodeficiency. Patients were randomly assigned to receive either amphotericin B (0.5 to 0.6 mg per kilogram of body weight per day) or fluconazole (400 mg per day), each continued for at least 14 days after the last positive blood culture. Outcomes were assessed by a group of investigators blinded to treatment assignment. RESULTS: Of the 237 patients enrolled, 206 met all entry criteria. The most common diagnoses were renal failure, nonhematologic cancer, and gastrointestinal disease. There was no statistically significant difference in outcome: of the 103 patients treated with amphotericin B, 81 (79 percent) were judged to have been treated successfully, as were 72 of the 103 patients treated with fluconazole (70 percent P = 0.22; 95 percent confidence interval for the difference, -5 to 23 percent). The bloodstream infection failed to clear in 12 patients in the amphotericin group and 15 in the fluconazole group; the species most commonly associated with failure was Candida albicans. There were 41 deaths in the amphotericin group and 34 deaths in the fluconazole group (P = 0.20). Intravascular catheters appeared to be the most frequent source of candidemia. There was less toxicity with fluconazole than with amphotericin B. CONCLUSIONS: In patients without neutropenia and without major immunodeficiency, fluconazole and amphotericin B are not significantly different in their effectiveness in treating candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“especially given that fluconazole is commonly used for the treatment of uncomplicated candidemia (32).”
In the citing paper
“Treatment failure occurred most frequently with C. albicans [26].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [26]
In the citing paper
“In randomized controlled clinical trials of nonneutropenic patients with candidemia, outcomes were similar for patients treated with fluconazole versus amphotericin B, but toxicity was more frequent with amphotericin B [26,27].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [26]
In the citing paper
“Two large randomized studies [105, 106] and 2 large observational studies [107, 108] have demonstrated that fluconazole (400 mg/day) and amphotericin B deoxycholate (0.5-0.6 mg/kg per day) are similarly effective as therapy.”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [105]
In the citing paper
“Although fungemia due to C. glabrata has been treated successfully with fluconazole (6 mg/kg per day) [105, 132]”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [105]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
Fungemia in a Cancer Hospital: Changing Frequency, Earlier Onset, and Results of Therapy
Horn, R., Wong, B., Kiehn, T. E., & Armstrong, D. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.5.646 · Cited by 480
Komshian, S. V., Uwaydah, A. K., Sobel, J. D., & Crane, L. R. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.3.379 · Cited by 457
EDWARDS, J. E., FOOS, R. Y., MONTGOMERIE, J. Z., & GUZE, L. B. (1974) · Medicine · doi:10.1097/00005792-197401000-00002 · Cited by 304
Self-citationKlein, J. J., & Watanakunakorn, C. (1979) · The American Journal of Medicine · doi:10.1016/0002-9343(79)90073-1 · Cited by 166
The Significance of Candidemia
ELLIS, C. A., & SPIVACK, M. L. (1967) · Annals of Internal Medicine · doi:10.7326/0003-4819-67-3-511 · Cited by 162
Candida Infections in Surgical Patients
Marsh, P. K., Tally, F. P., Kellum, J., Callow, A., & Gorbach, S. L. (1983) · Annals of Surgery · doi:10.1097/00000658-198307000-00008 · Cited by 152
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
“of AmB deoxycholate for the treatment of candidemia [21, 22] and is also considered to be standard therapy for oropharyngeal, esophageal, and vaginal candidiasis, as well as urinary tract in-”
BackgroundResultInfluentialSelf-citationEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
“Furthermore, mortality estimates based on the presence of Candida at sterile sites within 48 h of death or at autopsy (163, 188, 248) grossly underestimate”
BackgroundMermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
“8 Fluconazole can be used for patients without azole exposure in the previous 3 months and in health care settings where the risk of Candida krusei or Candida glabrata infection is very low A-III [184, 260]”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“Fluconazole remains standard therapy for selected patients with candidemia, on the basis of abundant data from welldesigned clinical trials [27, 28, 53, 79].”
BackgroundSelf-citationDaptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citation
Metadata
- Authors
- Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., Levenstein, M. J., & Webb, C. D.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- National Institutes of Health (US)
- Boston University (US)
- University of Alabama at Birmingham (US)
- Harbor–UCLA Medical Center (US)
- Atrium Health Wake Forest Baptist (US)
- University of Virginia (US)
- Pfizer (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-11-17
- Volume
- 331
- Issue
- 20
- Pages
- 1325-1330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2340388705
- Cited by
- 1,039
- References
- 14
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 8 · 2023: 5 · 2022: 5 · 2021: 20 · 2020: 12 · 2019: 13 · 2018: 16 · 2017: 19 · 2016: 9 · 2015: 22 · 2014: 20 · 2013: 24 · 2012: 32
- FWCI
- 47.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01ai015082-002)
- National Institute of Allergy and Infectious Diseases (N01 AI15082)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- candidemia, fluconazole, amphotericin B, antifungal therapy, Candida albicans, non-neutropenic patients, treatment efficacy, mortality, drug toxicity, bloodstream infection
- MeSH terms
- Amphotericin B, Candidiasis, Catheters, Indwelling, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neutropenia, Fluconazole, Fungemia, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia. https://app.cochat.ai/papers/10.1056/nejm199411173312001
- The paper
- Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., Levenstein, M. J., & Webb, C. D. (1994). A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia. New England Journal of Medicine. https://doi.org/10.1056/nejm199411173312001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.